Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.
about
Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so farCare and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesityThe endocannabinoid system as an emerging target of pharmacotherapyEndocannabinoids selectively enhance sweet tasteLipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and QuantificationMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationThe thrifty lipids: endocannabinoids and the neural control of energy conservationThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsExposure to a Highly Caloric Palatable Diet During Pregestational and Gestational Periods Affects Hypothalamic and Hippocampal Endocannabinoid Levels at Birth and Induces Adiposity and Anxiety-Like Behaviors in Male Rat Offspring.The endocannabinoid system: directing eating behavior and macronutrient metabolismHypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivityMapping brain circuits of reward and motivation: in the footsteps of Ann KelleyThe role of sex steroid hormones, cytokines and the endocannabinoid system in female fertilityPhysical activity and the endocannabinoid system: an overviewSleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-ArachidonoylglycerolNew horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolismObesity: Current and potential pharmacotherapeutics and targets.Cannabinoids, eating behaviour, and energy homeostasis.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available dataDifferential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brainThe orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.Dysregulation of the endocannabinoid system in obesity.Identification of endocannabinoids and related compounds in human fat cells.Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerolQuantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.[EXPRESS] AMP-activated kinase and the endogenous endocannabinoid system might contribute to antinociceptive effects of prolonged moderate caloric restriction in miceMutation screen and association studies for the fatty acid amide hydrolase (FAAH) gene and early onset and adult obesity.Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype.The endocannabinoid system: potential for reducing cardiometabolic riskModerate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperamentThe tempted brain eats: pleasure and desire circuits in obesity and eating disorders.GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus.Quantification of brain endocannabinoid levels: methods, interpretations and pitfallsEndocannabinoid signalling: has it got rhythm?The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
P2860
Q21090468-36C28F55-788A-4BEB-BC4C-B39D17110BD6Q21132308-10B79963-E9B9-454C-AFCF-1EC48F52A915Q24523292-2D699CC3-188B-47B8-B226-2C418F93E760Q24648473-C5660A40-B702-4C7A-9F7B-A76C31556695Q24651367-7CFE78CB-1088-4132-9B77-8896EBF7FA08Q26769959-5615FE6F-64E7-49ED-B514-52F706E09C29Q26829111-3A8970C9-1E94-4EFC-B3B3-D8EFF94735F5Q26996134-4DEF4D1B-7A51-4F06-BB5E-B342145C435BQ27009466-5A8EE581-301B-4552-8730-9E014C07CD9DQ27321798-E2CF4A68-D670-48A3-BA30-97B033CFD64FQ28086830-27B59CE3-C20B-4309-905F-A09B08CAF311Q28190374-936F0395-2DBE-4C96-BCA2-45021C4AE98AQ28242954-2DB603C0-40EF-4AE0-986F-DF495A53EA30Q28281971-36DE66F2-3EDD-4132-91F2-52C5E2E4800DQ28303095-9B0A0E1C-9263-4237-9338-5EBA50F5EABDQ28307668-47569F53-211B-4DD5-9F14-78E9E70FAED3Q28387665-DF554598-DBD0-4668-BF34-DC0CCD40FE6FQ28833783-18B2C1E3-D1AE-4C71-8171-540E1D9ACECCQ30243992-CB8EADC6-BF05-420F-9AF9-5E73B6A67158Q30357350-8AAEBF72-7686-4237-BB5A-344F91B9B064Q30473707-85F67DD9-8373-42CA-A2AC-0ADFCB78D98BQ30945416-C61AEDEB-3721-44EF-8FCC-046B5811AA18Q31059589-D5E2646D-4184-48D1-8454-85EA2385A490Q31116375-F8296CD5-CC8F-4765-B66D-9FC3D9A7E196Q33258602-C01477A2-F4A2-4EB5-9945-A5C884C85057Q33323392-4C9289CD-FAA9-4AC9-B074-21DF30EA7112Q33345484-B80FC902-1089-43C7-A5BF-4CFDA469A680Q33437059-0F626836-E425-4B3A-8805-6CF4CF68E482Q33587870-7F6E4E12-7C19-480F-BB97-963ED814EAF8Q33659650-30131B79-A10B-40B7-AA8F-FA1494DAB296Q33663266-E90C4057-6377-454D-AEE0-1E87F06EA3A8Q33698241-4E2E7C8C-92D9-459F-8684-A57014539FCEQ33994763-D61A3EC1-49FB-45A3-A8BF-7199B306C2CCQ33999727-FC54BFC2-44EE-4BA5-8497-9DE21E8150FAQ34015624-6FDFA58B-0866-48E6-9AC5-843B7E501517Q34032576-1D3B8E3F-AA7C-4A7F-BB9E-27E83D7A6D0CQ34056106-F0B5F222-335D-415E-A039-9C4BBA9743D0Q34098167-CB72AA7F-D64F-4578-BC04-0A5B23BBF72DQ34098217-2721A9BE-322A-4A82-B438-31C530861088Q34131412-92981EFA-92BB-4CF6-9914-A51BC1917A9C
P2860
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@en
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@nl
type
label
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@en
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@nl
prefLabel
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@en
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@nl
P2093
P2860
P356
P1476
Endocannabinoid levels in rat ...... ng by 2-arachidonoyl glycerol.
@en
P2093
Filomena Fezza
Tim C Kirkham
Vincenzo Di Marzo
P2860
P304
P356
10.1038/SJ.BJP.0704767
P407
P577
2002-06-01T00:00:00Z